Advocate-BREAST80+: A Comprehensive Patient and Advocate-Led Study to Enhance Breast Cancer Care Delivery and Patient-Centered Research in Women Aged ≥80 Years

There are limited evidence-based data to guide treatment recommendations for breast cancer (BC) patients ≥80 years (P80+). Identifying and addressing unmet needs are critical. Advocate-BREAST80+ compared the needs of P80+ vs. patients < 80 years (P80-). In 12/2021, a REDCap survey was electronica...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2024-07, Vol.16 (14), p.2494
Main Authors: O'Sullivan, Ciara C, Vierkant, Robert A, Larson, Nicole L, Smith, Mary Lou, Chauhan, Cynthia, Couch, Fergus J, Olson, Janet E, D'Andre, Stacy, Jatoi, Aminah, Ruddy, Kathryn J
Format: Article
Language:English
Subjects:
Advocacy
Anxiety
Breast cancer
Cancer
Cancer patients
Care and treatment
Clinical trials
Cohort analysis
Decision making
Evidence-based medicine
Metastasis
Oncology, Experimental
Patients
Polls & surveys
Questionnaires
Side effects
Surveys
Women
Womens health
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There are limited evidence-based data to guide treatment recommendations for breast cancer (BC) patients ≥80 years (P80+). Identifying and addressing unmet needs are critical. Advocate-BREAST80+ compared the needs of P80+ vs. patients < 80 years (P80-). In 12/2021, a REDCap survey was electronically circulated to 6918 persons enrolled in the Mayo Clinic Breast Disease Registry. The survey asked about concerns and satisfaction with multiple aspects of BC care. Overall, 2437 participants responded (35% response rate); 202 (8.3%) were P80+. P80+ were less likely to undergo local regional and systemic therapies vs. P80- ( < 0.01). Notably, P80+ were significantly less satisfied with information about the short and long-term side effects of BC therapies and managing toxicities. P80+ were also less likely to have participated in a clinical trial ( < 0.001) or to want to do so in the future ( = 0.0001). Although P80+ experienced less anxiety and symptom-related distress compared with P80-, they were significantly less satisfied with information regarding the side effects of BC therapies and their management. P80+ were significantly less likely to have participated in a clinical trial or be open to considering this option. Future studies should address educational needs pertaining to side effects and barriers to research participation in P80+.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers16142494